Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 2/2010

01-06-2010 | Review

Targeted therapies for non-clear renal cell carcinoma

Authors: Eric A. Singer, Gennady Bratslavsky, W. Marston Linehan, Ramaprasad Srinivasan

Published in: Targeted Oncology | Issue 2/2010

Login to get access

Abstract

The treatment of advanced and metastatic kidney cancer has been revolutionized by the development of targeted systemic therapies. Despite the growing number of available agents approved for use against clear cell renal cell carcinoma, patients with non-clear histologies, constituting approximately 1 in 4 cases of kidney cancer, have not received the same attention. The majority of clinical trials testing novel targeted therapies have excluded non-clear subtypes, providing limited therapeutic options for patients with these diagnoses and their oncologists. This review will focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma: papillary I and II, chromophobe, and collecting duct. The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them. Trials focusing on non-clear kidney cancer, or those that treated clear cell tumors along with significant numbers of non-clear subtypes, will be discussed. The role of cytoreductive nephrectomy and the use of neoadjuvant and adjuvant targeted therapy will be reviewed. Lastly, areas of future research will be highlighted.

Literature
  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249View ArticlePubMed
  2. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B (1997) The Heidelberg classification of renal cell tumours. J Pathol 183(2):131–133View ArticlePubMed
  3. Pfaffenroth EC, Linehan WM (2008) Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 8(6):779–790View ArticlePubMed
  4. Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Naure Rev Urol 7:277–285View Article
  5. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170(6 Pt 1):2163–2172View ArticlePubMed
  6. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R (2010) Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 61:329–343View ArticlePubMed
  7. Rini BI (2009) Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 27(19):3225–3234View ArticlePubMed
  8. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119–1132View ArticlePubMed
  9. Di Lorenzo G, Autorino R, Sternberg CN (2009) Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 56(6):959–971View Article
  10. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23):2477–2490View ArticlePubMed
  11. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) Von Hippel-Lindau disease. Lancet 361(9374):2059–2067View ArticlePubMed
  12. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112):1317–1320View ArticlePubMed
  13. Bratslavsky G, Sudarshan S, Neckers L, Linehan WM (2007) Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res 13(16):4667–4671View ArticlePubMed
  14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124View ArticlePubMed
  15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134View ArticlePubMed
  16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281View ArticlePubMed
  17. Yagoda A, Petrylak D, Thompson S (1993) Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20(2):303–321PubMed
  18. Nelson EC, Evans CP, Lara PN Jr (2007) Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 33(3):299–313View ArticlePubMed
  19. Chung PH, Linehan WM, Bratslavsky G (2010) Race determines histologic subtypes and stage of RCC: an analysis of the seer database. 2010 Genitourinary Cancers Symposium: Abstract 314
  20. Furge KA, Mackeigan JP, Teh BT (2010) Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol 11(6):571–578View ArticlePubMed
  21. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 16(1):68–73View ArticlePubMed
  22. Dharmawardana PG, Giubellino A, Bottaro DP (2004) Hereditary papillary renal carcinoma type I. Curr Mol Med 4(8):855–868View ArticlePubMed
  23. Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH (2006) Met expression in sporadic renal cell carcinomas. J Korean Med Sci 21(4):672–677View ArticlePubMed
  24. Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, Kovacs G (1998) Duplication and overexpression of the mutant allele of the met proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17(6):733–739View ArticlePubMed
  25. Zbar B, Glenn G, Lubensky I, Choyke P, Walther MM, Magnusson G, Bergerheim US, Pettersson S, Amin M, Hurley K (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153(3 Pt 2):907–912PubMed
  26. Sudarshan S, Linehan WM (2006) Genetic basis of cancer of the kidney. Semin Oncol 33(5):544–551View ArticlePubMed
  27. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, Walther MM, Choyke P, Linehan WM, Zbar B (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155(2):517–526PubMed
  28. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 98(6):3387–3392View ArticlePubMed
  29. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30(4):406–410View ArticlePubMed
  30. Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L (2007) Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13(2 Pt 2):671s–679sView ArticlePubMed
  31. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31(10):1578–1585View ArticlePubMed
  32. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of hif stability. Cancer Cell 8(2):143–153View ArticlePubMed
  33. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27(5):612–624View ArticlePubMed
  34. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23(12):2763–2771View ArticlePubMed
  35. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG (2008) Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 112(7):1480–1488View ArticlePubMed
  36. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in north america. Cancer 116(5):1272–1280View ArticlePubMed
  37. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schoffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763View ArticlePubMed
  38. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of su11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16–24View ArticlePubMed
  39. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524View ArticlePubMed
  40. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590View ArticlePubMed
  41. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20(9):2376–2381View ArticlePubMed
  42. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26(1):127–131View ArticlePubMed
  43. Plimack ER, Jonasch E, Bekele BN, Qiao W, Tamboli P, Ng CS, Tannir NM (2010) Sunitinib in papillary renal cell carcinoma (prcc): results from a single-arm phase ii study. J Clin Oncol 28:15s, suppl; abstr 4604
  44. Ravaud A, Oudard S, Gravis-Mescam G, Sevin E, Zanetta S, Theodore C, de Fromont M, Mahier-Ait Oukhatar C, Chene G, Escudier B (2009) First-line sunitinib in type I and II papillary renal cell carcinoma (prcc): Supap, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP). J Clin Oncol 27(15S):5146
  45. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202–209View ArticlePubMed
  46. NIH (2010) Raptor: Rad001 as monotherapy in the treatment of advanced papillary renal cell tumors program in europe (raptor/lfr08). Available from: http://​clinicaltrials.​gov/​ct2/​show/​NCT00688753?​term =​ RAPTOR&​rank =​ 2 [cited June 27, 2010]
  47. Srinivasan R, Linehan WM, Vaishampayan U, Logan T, Shankar SM, Sherman LJ, Liu Y, Choueiri TK (2009) A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 27(15S (post-meeting addition)):Abstract 5103
  48. Gordon MS, Hussey M, Nagle RB, Lara PN Jr, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D (2009) Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: Swog s0317. J Clin Oncol 27(34):5788–5793View ArticlePubMed
  49. NIH (2010) A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. Available from: http://​clinicaltrials.​gov/​ct2/​show/​NCT01130519?​term =​ bevacizumab + and + erlotinib&​rank =​ 2 [cited June 27, 2010]
  50. Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L, Walther M, Choyke P, Weirich G, Hewitt SM, Duray P, Gabril F, Greenberg C, Merino MJ, Toro J, Linehan WM (2002) Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev 11(4):393–400PubMed
  51. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ (2002) Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 26(12):1542–1552View ArticlePubMed
  52. Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR, Turner ML, Duray P, Merino M, Hewitt S, Pavlovich CP, Glenn G, Greenberg CR, Linehan WM, Zbar B (2001) Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69(4):876–882View ArticlePubMed
  53. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2(2):157–164View ArticlePubMed
  54. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, Turner ML, Choyke PL, Sharma N, Peterson J, Morrison P, Maher ER, Walther MM, Zbar B, Linehan WM (2005) Germline bhd-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 76(6):1023–1033View ArticlePubMed
  55. Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, Merino MJ, Walther MM, Zbar B, Linehan WM (2005) High frequency of somatic frameshift bhd gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst 97(12):931–935View ArticlePubMed
  56. Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM (2009) Homozygous loss of bhd causes early embryonic lethality and kidney tumor development with activation of mTORc1 and mTORc2. Proc Natl Acad Sci U S A 106(44):18722–18727View ArticlePubMed
  57. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S (2003) Overexpression of kit in chromophobe renal cell carcinoma. Oncogene 22(6):847–852View ArticlePubMed
  58. Fleming S, Lewi HJ (1986) Collecting duct carcinoma of the kidney. Histopathology 10(11):1131–1141View ArticlePubMed
  59. Heng DY, Choueiri TK (2009) Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 7(6):659–665PubMed
  60. Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arakelyan N, Culine S (2007) Prospective multicenter phase ii study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’etudes des tumeurs uro-genitales) study. J Urol 177(5):1698–1702View ArticlePubMed
  61. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2B compared with interferon alfa-2B alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659View ArticlePubMed
  62. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071–1076View ArticlePubMed
  63. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970View ArticlePubMed
  64. Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A, Merino M, Rosenberg SA (1990) Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144(3):614–617, discussion 617–618PubMed
  65. Spencer WF, Linehan WM, Walther MM, Haas GP, Lotze MT, Topalian SL, Yang JC, Merino MJ, Lange JR, Pockaj BA et al (1992) Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol 147(1):24–30PubMed
  66. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC (1999) Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162(1):43–45View ArticlePubMed
  67. Rini BI, Campbell SC (2007) The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177(6):1978–1984View ArticlePubMed
  68. Rini BI (2005) VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 10(3):191–197View ArticlePubMed
  69. Abel EJ, Wood CG (2009) Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 6(7):375–383View ArticlePubMed
  70. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG (2007) Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 178(5):1896–1900View ArticlePubMed
  71. Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA (2009) Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 106(2):218–223View ArticlePubMed
  72. Shuch B, La Rochelle JC, Wu J, Klatte T, Riggs SB, Kabbinavar F, Belldegrun AS, Pantuck AJ (2008) Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer 113(6):1324–1331View ArticlePubMed
  73. Rathmell WK, Pruthi R, Wallen E (2010) Neoadjuvant treatment of renal cell carcinoma. Urol Oncol 28(1):69–73PubMed
  74. Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS (2008) Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 102(6):692–696View ArticlePubMed
  75. Margulis V, Wood CG (2009) Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int 103(2):150–153View ArticlePubMed
  76. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D (2003) Phase III study of interferon alfa-nl as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21(7):1214–1222View ArticlePubMed
  77. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19(2):425–431PubMed
  78. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M (2005) Adjuvant treatment with interleukin-2- and interferon-alpha2A-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92(5):843–846View ArticlePubMed
  79. NIH (2010) Clinical trials basic search. Available from: http://​clinicaltrials.​gov/​ct2/​search [cited June 27,2010]
  80. Margulis V, Matin SF, Wood CG (2008) Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol 18(5):474–480View ArticlePubMed
  81. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94–98View ArticlePubMed
  82. Buchanan DR, O’Mara AM, Kelaghan JW, Minasian LM (2005) Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported community clinical oncology program. J Clin Oncol 23(3):591–598View ArticlePubMed
  83. Saylor PJ, Michaelson MD (2009) New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 7(6):645–656PubMed
  84. Liu J, Mittendorf T, von der Schulenburg JM (2010) A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 28(3):312–322View ArticlePubMed
Metadata
Title
Targeted therapies for non-clear renal cell carcinoma
Authors
Eric A. Singer
Gennady Bratslavsky
W. Marston Linehan
Ramaprasad Srinivasan
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Targeted Oncology / Issue 2/2010
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-010-0148-3

Other articles of this Issue 2/2010

Targeted Oncology 2/2010 Go to the issue

Review

Targeted therapies in renal cell cancer: recent developments in imaging

Perspectives

Perspectives in drug development for metastatic renal cell cancer

Editorial

Renal cell carcinoma: ten years of significant advances

Review

Targeted therapies for renal cell carcinoma: understanding their impact on survival

Review

Targeted therapy for locally advanced renal cell carcinoma

Review

Emerging molecular classification in renal cell carcinoma: implications for drug development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits